Macro- and micronutrients in patients with congestive heart failure, particularly African-Americans by Newman, Kevin P et al.
Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Not all patients with heart failure, deﬁ  ned as a reduced ejection fraction, will have 
an activation of the RAAS, salt and water retention, or the congestive heart failure (CHF) 
syndrome. Beyond this cardiorenal perspective, CHF is accompanied by a systemic illness 
that includes oxidative stress, a proinﬂ  ammatory phenotype, and a wasting of soft tissues and 
bone. A dyshomeostasis of calcium, magnesium, zinc, selenium, and vitamin D contribute to 
the appearance of oxidative stress and to compromised endogenous defenses that combat it. A 
propensity for hypovitaminosis D, given that melanin is a natural sunscreen, and for second-
ary hyperparathyroidism in African-Americans make them more susceptible to these systemic 
manifestations of CHF—a situation which is further threatened by the calcium and magnesium 
wasting that accompanies the secondary aldosteronism of CHF and the use of loop diuretics.
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Introduction
Approximately 4.8 million Americans suffer from congestive heart failure (CHF) 
with an estimated 400,000 new cases diagnosed each year. Congestive heart failure 
is a clinical syndrome based on left ventricular dysfunction which results in salt and 
water retention and effort incapacity mediated by hormonal factors, most notably 
the renin-angiotensin-aldosterone and the sympathetic nervous systems (Anand et al 
1989; Francis et al 1990; Swedberg et al 1990; Villarreal et al 1993; Weber 2001; 
Jessup and Brozena 2003). While pharmacologic blockade of these systems improves 
survival and quality of life (The SOLVD Investigators 1991; Pitt et al 1999), less well 
recognized are the roles played by micronutrients such as vitamins, zinc and selenium, 
and macronutrients, especially calcium and magnesium.
Oxidative stress
An important component of the CHF syndrome is the generation of cytotoxic reactive 
oxygen and nitrogen species, together with a reduction in antioxidant defenses (Molavi 
and Mehta 2004; Wykretowicz et al 2004; Ungvari et al 2005). Two such defenses 
are Cu/Zn-superoxide dismutase (SOD) and Se-glutathione peroxidase (GSH-Px), 
which serve as O2
- and H2O2 scavengers (Itoh et al 2004) and are dependent upon 
zinc and selenium bioavailability (Xia et al 1989; Thakur et al 2004). Secondary 
hyperparathyroidism, a covariant of chronic renal failure due to hypovitaminosis D and 
the resultant inability to absorb calcium from the intestine, is also common in patients 
with heart failure (Lee et al 1994; Shane et al 1997; Arroyo et al 2006; Khouzam et al 
2006; LaGuardia et al 2006). The secondary hyperparathyroidism due to reduced 
plasma-ionized Ca2+ and Mg2+ secondary to increased urinary and fecal calcium excre-
tion is noted in rats administered aldosterone in quantities one would expect to ﬁ  nd in Vascular Health and Risk Management 2006:2(4) 465–475
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CHF (Chhokar et al 2004; Chhokar et al 2005). Secondary 
hyperparathyroidism not only increases bone resorption to 
free up calcium and magnesium but paradoxically drives 
calcium intracellularly, a potent stimulus for oxidative and 
nitrosative stress.
Macronutrient deﬁ  ciency 
in congestive heart failure
Shane et al (1997) evaluated 101 predominantly Caucasian 
patients with severe (NYHA class III or IV) CHF referred 
for cardiac transplantation. Serum 25 hydroxyvitamin D 
(25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D3), 
and intact parathyroid hormone (PTH) were monitored. 
25(OH)D and 1,25(OH)2D3 levels were reduced in 17% and 
26% of these patients, respectively, while PTH levels were 
elevated in 30%. Likewise, Stefenelli et al (1992) also found 
elevated PTH levels in 5 of 27 Caucasian patients (18.5%) 
with advanced CHF. As noted above, experimental studies 
of aldosteronism in rats have demonstrated urinary and fecal 
losses of calcium together with excessive intracellular cal-
cium accumulation and increased H2O2 production. Calcium, 
as well as magnesium, sodium, and potassium are examples 
of macronutrients, and as such are crucial for homeostasis. 
In the study by Shane et al there is, not surprisingly in light 
of the lower 25(OH)D and 1,25(OH)2D3 levels and calcium 
loss, clear evidence of increased bone turnover.
Loop diuretics such as furosemide have been shown 
to adversely affect calcium and bone homeostasis. Stein 
et al (1996) assessed serum 25(OH)D, PTH, creatinine, and 
a variety of medications, including loop diuretics, in 251 
nursing home residents. Fifty-two percent had 25(OH)D 
reduced below the normal level, and PTH above the upper 
limit of the reference value. Daily furosemide dosing was an 
important predictor of elevated PTH levels. In summary, both 
animal and clinical data support the contention that CHF is 
associated with secondary hyperparathyroidism, most likely 
accentuated by the use of loop diuretics.
African-Americans 
and hypovitaminosis D
Because of the higher melanin content in the skin of African-
Americans, which serves as a sunscreen, one would expect 
a relatively suboptimal production of vitamin D. Perry et al 
(1993) measured 25(OH)D, PTH, osteocalcin, and calcito-
nin levels in 32 African-Americans aged 68–93, and in 43 
white Americans aged 70–89, none of whom were receiv-
ing thiazide diuretics. Thirty-eight percent of the African-
American men and 38% of the African-American women 
had 25(OH)D levels <8 ng/mL, compared to 22% of the 
Caucasian men and 40% of Caucasian women. PTH was 
above the normal range in 25% of the African-American 
men and 33% of the African-American women compared 
to 14% and 30%, respectively, for the Caucasian men and 
women. Bikle et al (1999) assessed 25(OH)D levels, during 
the summer and winter months, in 109 black men, 114 white 
men, 95 black women, and 84 white women. Not only were 
25(OH)D levels lower among the black subjects, but the 
values of this essential vitamin were 19%–29% lower in the 
winter than in the summer irrespective of race and gender. 
Fuleihan et al (1994) studied the response of PTH to hypo- 
and hypercalcemia in six healthy white and six healthy black 
volunteers, with results showing incremental values of 9.2 
and 0.7 pmol/L among the African-Americans, and 6.9 and 
0.3 pmol/L among the Caucasian subjects. These authors 
concluded that African-Americans demonstrate a greater 
propensity to express mild hyperparathyroidism under a 
provocative hypocalcemic challenge.
African-Americans with congestive 
heart failure; incidence of secondary 
hyperparathyroidism
Khouzam et al (2006) monitored serum PTH and calcium 
levels in 9 patients, hospitalized with CHF and left ven-
tricular systolic dysfunction (ejection fraction <35%), 8 of 
whom were African-Americans. In all patients, serum PTH 
levels were consistently elevated above the reference value 
(65 pg/mL) despite normal calcium levels. In 5 patients with 
previously untreated CHF, plasma PTH ranged from 86 to 
393 pg/mL, whereas PTH in the 4 patients with previously 
treated CHF ranged from 105–164 pg/mL. Arroyo et al. 
(2006), from the same group, studied 40 African-American 
patients with CHF divided into protracted (4 weeks, 15 
inpatients), shorter duration (1–2 weeks, 15 inpatients), and 
compensated (10 outpatients). The serum PTH was elevated 
in all of the patients with protracted failure, in 60% of the 
patients with shorter duration failure, and in none of the 
compensated group. Likewise, serum-ionized calcium and 
magnesium concentrations were reduced in the “decompen-
sated” groups. Hypovitaminosis D, with serum 25(OH)D 
levels <30 ng/mL, was found in all protracted heart failure 
patients and in 80% of the group with symptoms for 1–2 
weeks. Eighty percent of the compensated patients were 
found to have subnormal 25(OH)D levels, whereas 9 Afri-
can-American volunteers without evidence of cardiovascular Vascular Health and Risk Management 2006:2(4) 465–475
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Nutrients in heart failure
disease serving as controls tested euparathyroid with normal 
25(OH)D values. Thus, CHF in African-Americans is associ-
ated with secondary hyperparathyroidism, with inadequate 
exposure to sunlight appearing to be an attractive but un-
proven etiology for this condition. Other etiologic factors 
are aldosteronism with elevated urinary and fecal losses of 
calcium, and the calciuric effect of loop diuretics.
Micronutrient deﬁ  ciencies 
in aldosteronism and congestive 
heart failure
Micronutrients exist only in minute amounts and func-
tion in their primary role as coenzymes in antioxidant 
reactions. Zinc, copper, and selenium are all examples of 
micronutrients, the primary source of which is dietary. Zinc 
deﬁ  ciency has been well described in conditions of stress, 
such as sepsis, trauma, and malnutrition; these conditions 
are associated with a decline in Cu/Zn-SOD activity, an im-
portant antioxidant defense (Thakur et al 2004). When rats 
are administered aldosterone to raise serum levels to those 
one would expect in CHF, they exhibit signiﬁ  cant zincuria 
together with depressed activity of Cu/Zn-SOD (Thomas 
et al 2007). Ripa et al (1998) investigated the relationship 
between CHF and zinc and copper levels in blood, urine, 
and red blood cells in normal volunteers, in 15 patients with 
dilated cardiomyopathy, and in 11 patients with hypertrophic 
cardiomyopathy. Zincuria with low plasma and erythrocyte 
zinc levels was found in patients with dilated cardiomyopa-
thy, whereas plasma and erythrocyte levels were depressed 
in those with hypertrophic cardiomyopathy without zincuria. 
The authors speculate a causative role for an atrial natriuretic 
peptide in promoting zincuria. CHF may be associated with 
a deﬁ  ciency of plasma zinc; medications, particularly angio-
tensin-converting enzyme inhibitors and angiotensin receptor 
blockers, result in an increased urinary excretion of zinc 
(Cohanim and Yendt 1975; Wester 1980; Zumkley et al 1985; 
Abu-Hamdan et al 1988; Koren-Michowitz et al 2005). The 
role of nutrient supplementation in CHF, particularly that of 
zinc and selenium, is not well appreciated at this time, but 
warrants investigation.
Selenium is an important cofactor in antioxidant 
enzymatic reactions which aid cellular and humoral immunity 
(Kidd 2003). Selenium deﬁ  ciency is associated with cardio-
myopathy in a certain area of China, the Keshan province, 
where selenium is depleted in the soil, and in patients receiv-
ing parenteral nutrition without selenium supplementation 
(Quercia et al 1984; Xia et al 1989; Oster 1993; Levy et al 
1994; Huttunen 1997; Vijaya et al 2000). A cardiomyopa-
thy linked to selenium deﬁ  ciency is so endemic to Keshan 
province of China that the disease now bears the name of 
this area. Xia et al (1989) sampled blood from healthy young 
men from Dechang County, China, for selenium levels and 
glutathione peroxidase activity, and compared these values 
to those from subjects from Mianning County, where sodium 
selenite is added to salt and Keshan disease is rare. Plasma 
selenium concentrations from the Dechang group were 33 and 
38% (boys and men) those of the Mianning group. Likewise, 
the glutathione peroxidase activity from Dechang (boys and 
men) was 33% and 43% that of the Mianning group. Daily 
selenium supplementation (100 mcg for boys and 200 mcg 
for men) improved these values, implying that Keshan dis-
ease may be prevented or ameliorated. However, the role 
of selenium deﬁ  ciency in atherosclerotic coronary disease 
remains controversial (Huttunen 1997).
Levy et al (1994) reported a case of reversible cardiomy-
opathy in a patient receiving selenium-deﬁ  cient parenteral 
nutrition. Quercia et al (1984) measured selenium concen-
trations in plasma, heart, kidney, and liver from a patient 
who died of a cardiomyopathy while receiving long-term 
intravenous nutrition. Such values were 5%–12% of normal 
values. The role of selenium deﬁ  ciency in more usual forms 
of dilated cardiomyopathy not associated with parenteral 
nutrition has been less well investigated. Vijaya et al (2000) 
measured serum selenium values in 37 patients with dilated 
cardiomyopathy, and found that these values were 27% those 
of the normal controls. This study did not address other risk 
factors, but there was a high incidence of alcohol intake 
among their patients.
Congestive heart failure is associated with deﬁ  ciencies of 
plasma zinc and selenium. The etiology of such deﬁ  ciencies 
is multifactorial, including medications and malnutrition; the 
role of micronutrient supplementation as a therapy for this 
syndrome has not been investigated.
Micronutrient deﬁ  ciencies 
in African-Americans with 
congestive heart failure
Arroyo et al (2006) in the aforementioned study of 40 
African-American patients with protracted, short-lived, 
and compensated CHF, examined serum zinc and selenium 
values. In the protracted group, 70% were hypozincemic 
and 100% exhibited selenium values below normal. Such 
values among the short-lived group were 50% and 60% re-
spectively, compared to 50% and 100% in the compensated Vascular Health and Risk Management 2006:2(4) 465–475
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outpatient group. Thus, micronutrient values not only reﬂ  ect 
the condition of CHF, but may indicate its severity.
Summary and conclusion
Congestive heart failure is a state of aldosteronism charac-
terized by salt and water retention; catecholamine excess 
is another key component of this syndrome. Less well 
recognized is the presence of altered calcium levels, para-
thyroid homeostasis with hypovitaminosis D and secondary 
hyperparathyroidism, particularly in African-Americans. 
The mechanisms of secondary hyperparathyroidism and 
hypovitaminosis D are multiple. For example, aldosterone 
excess leads to increased urinary and fecal calcium losses 
with a resultant fall in serum-ionized Ca2+ and Mg2+, thereby 
stimulating parathyroid secretion. Furthermore, loop diuret-
ics cause calciuria and magnesuria. Sunlight is critical to 
vitamin D synthesis and lack of its exposure to bare skin 
becomes a crucial issue in patients with symptomatic CHF 
who are likely to be home- or hospital-bound. The increased 
melanin content of the skin of African-Americans causes 
a relative resistance to sunlight making them more at risk 
of hypovitaminosis D. The role of sunlight or ultraviolet B 
light exposure in the treatment of this syndrome remains to 
be investigated.
Hypozincemia and hyposelenemia are commonly 
observed in CHF patients, particularly African-Americans, 
and a deﬁ  ciency of these antioxidant cofactors can lead to 
oxidative stress. Malnutrition is the most likely etiology for 
micronutrient deﬁ  ciencies, although angiotensin-converting 
enzyme inhibitors and angiotensin receptor blocking agents 
cause hyperzincuria. Based upon the experience with zinc 
supplementation in patients receiving parenteral nutrition, one 
would expect a direct beneﬁ  t from dietary supplementation.
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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